Clinical Trials Browser

Interventional × Has results × Ascites × Clear all

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02638051 2017-05-19

OTMA-RII

Phase 2 Completed

260 enrolled 13 charts

Gynecologic

Ascites, Peritoneal Neoplasms, Yin Deficiency, Yang Deficiency

NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Phase 2 Terminated

1 enrolled 10 charts

GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT00327444 2013-01-01

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Phase 2/3 Completed

58 enrolled 11 charts

Gynecologic

Ascites, Ovarian Neoplasms

NCT00005906 2010-04-30

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Phase 2 Completed

4 enrolled 8 charts

Thoracic

Ascites, Chylous Ascites, Chylothorax, Lymphangiomyoma, Pleural Effusion, Lymphangioleiomyomatosis

Clinical Trials

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

OTMA-RII

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis